(3R,5R)-5-Methylpiperidin-3-ol | 1354392-05-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3R,5R)-5-Methylpiperidin-3-ol
• CAS: 1354392-05-4
• 化学式: C₆H₁₃NO
• 分子量: 115.17
• InChiKey: QDPYHRSTDJTFRG-PHDIDXHHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Isoxazole carboxamide compounds
  申请人：EPIZYME, INC.

  公开号：US10428029B2

  公开（公告）日：2019-10-01

  The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供了具有式（I）的取代异噁唑羧酰胺化合物及其药学上可接受的盐和溶液，其中R1、R2、A、X和Z的定义如说明书所述。本公开还涉及使用式 I 的化合物治疗对 SMYD 蛋白如 SMYD3 或 SMYD2 的阻断有反应的紊乱。本公开的化合物尤其适用于治疗癌症。
• Isoxazole Carboxamide Compounds
  申请人：EPIZYME, INC.

  公开号：US20170190676A1

  公开（公告）日：2017-07-06

  The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
• Substituted Pyrrolidine Carboxamide Compounds
  申请人：EPIZYME, INC.

  公开号：US20170247326A1

  公开（公告）日：2017-08-31

  The present disclosure provides pyrrolidine carboxamide compounds having Formula I and the pharmaceutically acceptable salts and solvates thereof, wherein A, B, X, Y, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
• Substituted Pyrrolidine Compounds
  申请人：EPIZYME, INC.

  公开号：US20170253601A1

  公开（公告）日：2017-09-07

  The present disclosure provides substituted pyrrolidine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
• SMYD Inhibitors
  申请人：EPIZYME, INC.

  公开号：US20170355695A1

  公开（公告）日：2017-12-14

  The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.